Table 4 Comparison of clinical and demographic features based on ≥50% and ≥75% response rates in the 82 patients who completed the 12-week follow-up

Age, yrs

44.4±16.4

45.8±13.8

0.717

44.7±16.4

46.5±11.3

0.780

Females

27 (96.4)

48 (88.9)

0.247

48 (92.3)

27 (90.0)

0.719

BMI

23.5±3.4

233±3.3

0.899

23.5±3.4

23.1±3.3

0.622

Age at onset, yrs

14.1±5.2

15.7±6.9

0.518

15.2±6.5

14.9±6.5

0.843

Disease duration, yrs

30.3±15.7

30.0±13.9

0.996

29.5±16.0

31.1±11.5

0.767

MHD+MMD

19.5±8.6

16.3±7.1

0.073

18.5±8.1

15.4±6.8

0.105

NRS score

8±1.1

8.1±1.0

0.609

7.9±1.0

8.2±1.0

0.276

Unilateral pain

2 (7.1)

9 (16.7)

0.230

6 (54.5)

5 (16.7)

0.512

UAS

12 (43.0)

17 (31.5)

0.307

19 (36.5)

10 (33.3)

0.770

CAPS

1.3±1.6

1.1±2.0

0.426

1.0±5.4

1.3±2.4

0.935

Allodynia

4 (14.3)

10 (18.5)

0.629

9 (17.3)

5 (16.7)

0.941

ASC-12

2.5±3.6

2.1±3.8

0.498

2.7±3.7

1.7±3.9

0.071

Dopaminergic symptoms

11 (39.3)

13 (24.1)

0.15

19 (36.5)

5 (16.7)

0.057

MAI

19.6±10.4

17.9±10.7

0.361

18.9±11.4

17.8±8.8

0.792

Pts using concomitant prophylaxis

11 (39.3)

16 (29.6)

0.378

19 (36.5)

8 (26.7)

0.360

Prior treatment failures

4.9±2.5

4.1±2.3

0.087

4.9±2.6

3.3±1.7

0.001

Pts with prior treatment failures with CGRP-mAbs

16 (57.1)

18 (33.3)

0.038

28 (50.0)

8 (26.7)

0.039

Pts with prior treatment failure to OnabotulinumtoxinA

5 (62.5)

6 (66.7)

0.627

9 (64.3)

2 (66.7)

0.938

Pts with >1 comorbidity

21 (75.0)

27 (50.0)

0.029

36 (69.2)

12 (40.0)

0.010

Pts with psychiatric comorbidities

14 (50.0)

13 (24.1)

0.018

23 (44.2)

4 (13.3)

0.004

HIT-6

65.3±10.1

64.0±9.1

0.236

65.4±8.7

62.8±10.5

0.120

MIDAS

105.0±89.4

73.1±66.1

0.060

87.1±76.1

78.8±76.8

0.349

MIBS-4

9.5±3.7

9.0±3.3

0.387

9.3±3.4

8.9±3.6

0.606